• To introduc e the evidenc e-based medic ine in this c ontext. EBM also help in the disc ussion with the c linic ians and in the reading of published papers.
• What are the quality and turn-around-time requirements for these tests?
H istory
Before the era of tests for the troponins, the diagnosis was based on three c omponents; c linic al signs and symptoms, ECG-c hanges and level of c ardiac enzymes. As the evidenc e ac c umulated that a small release of troponins ( and CK-MB) is important as a prognostic marker for the individual patients, this c reated the need for new diagnostic c riteria.
Present
Many tests, eg. for the measurement of c ardiac troponin I, are available. The standardisation and c hoic e of antibodies of these tests are essential; there are several-fold differenc es in measured levels and also the time range for positivity is variable. The work of the IFCC c ommittee ( C-SMCD) ( Chairman Dr. Panteghini) is set to dec ide the standardisation.
N ew markers
Both faster ( fatty-ac id binding protein) and more sensitive tests ( next-generation troponin tests) will be available. Also tests whic h will detec t plaque-rupture may be developed. Last year the first paper to show the possibilities of pregranc y-assoc iated plasma protein A ( PAPP-A) measurement was published. New markers for platelet adhesion or markers to identify subgroups with inc reased risk ( natriuretic peptides; ANP and BNP for heart failure) will be available. They should be analysed together with established markers. If put in prac tic e, they should show extra benefit in the identific ation of new patients with inc reased risk, in addition to the c urrent markers. This would also c reate new problems with the interpretation of these markers.
Some c urrent examples and problems in evaluation of new c ardiac markers are introduc ed and disc ussed. The use of ROC c urves in the evaluation of new diagnostic tests is shown.
CRP
C-reac tive protein is a non-spec ific marker for inflammation. As a risk marker, slightly inc reased levels indic ate risk for c ardiovasc ular death in the follow-up studies. In the early phases of ac ute myoc ardial infarc tion, levels of 7 -2 0 mg/l ( depending on the studies and patient groups) define patients with inc reased risk, whic h is additional to the risk indic ated by troponin levels. This is, however, not easy to translate for the c linic ian, who will make dec isions. Smoking, other inflammatory diseases and other life-style fac tors may influenc e these risk markers. Other inflammatory markers studied inc lude other ac ute phase proteins and c ytokines.
Organisation of laboratory tests for acute heart diseases
Turn-around time ( TAT) is interesting for the c linic al unit as they use the test results in order to make c linic al dec isions. It depends on the individual organisation how they use it and what are the requirements. There is a general requirement of 1 hour for TAT set for c ardiac markers if they are used for ac ute dec isions. Disc ussion between the laboratory and the c linic al partners are required to understand and disc uss the use and availability of these tests. If the requirements are not met, the c linic al unit may want organize their own tests, with point-of-c are ( POC) analysers. In this setting it is advisable to organise the quality assuranc e programme and user training sc hedules with the support of the laboratory. Also the interfac e into the laboratory information system ( LIS) should be disc ussed.
Evidence-based Medicicne (EBM)
The c linic al use should be based on published, wellc ontrolled studies. This would result in the use of testspec ific c ut-offs and dec ision limits. Correlation of one spec ific method with another one is not enough, but c linic al follow-up studies are needed. The c linic al endpoints inc lude c ardiac death, interventions and operations for c ardiac disease and number of hospital admissions etc . The c linic al c hemist/laboratory physic ian should be aware of c urrent published papers, as there are new tests c ontinually being produc ed. The analysis of patients in the paper is very essential, inc luding follow-up studies or other methods to define the c linic al outc ome ( eg. ec hoc ardiography for heart failure etc .) . The introduc tion of national or worldwide guidelines are important to deliver a c lear message.
Interpretation in the clinic
The use of c ut-offs for c linic al dec isions should be introduc ed by the laboratory together with the c linic al units ( c ardiology) . The use, TAT and availability should be c lear for the c linic ians. The lag-time ( before the rise in the serum level) after the onset of pain or equivalent, the influenc e of ECG findings, heart failure, renal failure and rhabdomyolysis should be disc ussed. The new-generation tests ( e.g. more sensitive troponin-tests) should be c onsidered, if they provide extra benefit for the riskevaluation.
Point-of-Care (POC) tests
As the diagnostic industry is produc ing more and more new POC tests and analytes, there is a need for the c linic al c hemist to understand the evaluation of new tests that are markers for c ardiac diseases. The c ut-off levels and dec ision limits of these tests should also be based on c linic al studies with relevant end-points and follow-up studies. The available laboratory tests should be c onsidered as a relevant pac kage, together with the c linic ians involved.
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